Bhamare Sulabhchandra, Prabhakar Pimparkar, Dharmadhikari Aniruddha, Dedeepiya Vidyasagar Devaprasad, Terunuma Hiroshi, Senthilkumar Rajappa, Srinivasan Thangavelu, Reena Helen C, Preethy Senthilkumar, Abraham Samuel J K
The Mary-Yoshio Translational Hexagon, Nichi-In Centre for Regenerative Medicine, Chennai, Tamil Nadu, India; Yamanashi University-School of Medicine, Chuo, Japan.
J Cancer Res Ther. 2014 Jul-Sep;10(3):752-4. doi: 10.4103/0973-1482.136048.
Advanced gall bladder cancer generally has a poor prognosis and also shows decreased response to conventional therapies like chemotherapy and radiotherapy. Though surgical resection is the most common approach followed, the 1-year survival rate is only 10%. Herein, we report the outcome of administration of autologous natural killer cell and activated T lymphocyte-based autologous immune enhancement therapy (AIET) in a case of gall bladder cancer stage IV which was progressing in spite of surgical resection and several sittings of chemotherapy. There were no adverse reactions after AIET. After three infusions of AIET, an improvement of the quality of life and general condition which is sustaining for more than 6 months and a substantial decrease in the CA 19-9 marker levels from 2938.22 U/mL before AIET to 511 U/mL, 5 months after AIET, in our experience make us recommend AIET along with other conventional treatments in similar cases.
晚期胆囊癌通常预后较差，对化疗和放疗等传统疗法的反应也较低。虽然手术切除是最常用的方法，但1年生存率仅为10%。在此，我们报告了1例IV期胆囊癌患者接受基于自体自然杀伤细胞和活化T淋巴细胞的自体免疫增强疗法（AIET）的治疗结果，该患者尽管接受了手术切除和多次化疗仍病情进展。AIET后未出现不良反应。在三次输注AIET后，患者生活质量和总体状况得到改善并持续超过6个月，且CA 19-9标志物水平从AIET前的2938.22 U/mL大幅降至AIET后5个月的511 U/mL。根据我们的经验，建议在类似病例中将AIET与其他传统治疗方法联合使用。
